Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Zoom: 7.8% Free Cash Flow Yield And $6B In Cash, With No Debt (NASDAQ:ZM)

Security Solutions Today: Jul-Aug 2020 by Security Solutions Today - Issuu

SEC Filing – Royalty Pharma

S-1/A

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors

Amendment No. 1 to Draft Registration Statement

March 2016 Baltimore Beacon by The Beacon Newspapers - Issuu

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

SEC Filing – Royalty Pharma